Information  X 
Enter a valid email address

Diurnal Group PLC Ord GBP0.05 (DNL)

Related News

25-Apr-2022 07:19 PM

IN BRIEF: Diurnal expands distribution agreement with EffRx

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Extends distribution and marketing agreement with EffRx Pharmaceuticals in Switzerland to include Efmody. In October 2020, EffRx gained the exclusive
04-Apr-2022 10:06 AM

IN BRIEF: Diurnal CEO resigns immediately; CFO Bungay interim CEO

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Says Martin Whitaker has resigned as chief executive officer and as a member of the board, effective immediately. Chief Financial Officer Richard Bungay acts
30-Mar-2022 02:04 PM

Diurnal signs Alkindi distribution agreement with Vector Pharma

Diurnal Group PLC on Wednesday announced a distribution agreement for Alkindi with Vector Pharma, a full-service distribution provider. Under the agreement, Vector Pharma will receive exclusive rights to distribute Alkindi to 14 countries in th
10-Feb-2022 08:10 PM

IN BRIEF: Diurnal says patient dosed in adrenal insufficiency probe

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Says first patient dosed in its Phase 2 European clinical trial of modified-release hydrocortisone DNL-0200, once referred to as Chronocort. It is being deve
23-Feb-2021 09:32 AM

Diurnal losses widen in H1 on higher costs; eyes Chronocort European launch in Q3

Pharmaceutical group Diurnal reported a wider losses the first half of the year on higher expenses. For the six months ended 31 December 2020, pre-tax losses widened to £5.2 million from £4.5 million, while financial income £56k (si
15-Apr-2020 02:16 PM

Diurnal continues to run clinical trials; experiences no regulatory delays

Endocrine disease focused Diurnal said it was continuing to run clinical trial work and expected to have a enough cash to see it through to profitability despite the Covid-19 pandemic. Participating centres in Diurnal's currently ongoing clinical tr
11-Feb-2020 08:27 AM

Diurnal more than halves losses as costs shrink, revenue jumps

Pharmaceutical company Diurnal more than halved first-half losses as revenue jumped and R&D costs fell sharply. For the six months ended 31 December 2019, pre-tax losses more than halved to £4.5m from £9.6m on-year as revenues rose to £
08-Aug-2019 08:09 AM

Derwent profits lifted by higher net rental income

Derwent reported an uptick in profits on the back higher net rental income and an increased in the value of its property portfolio in the first half of the year. For the 6 months to 31 March, earnings -- stated as EPRA net asset value per share -- ro
15-May-2018 09:41 AM

Diurnal to present on 31 May 2018 at the Shares and AJ Bell Spotlight Evening in Edinburgh

Finding investment ideas for your portfolio. If you are a new investor just starting to invest on your own or a well-experienced one, many investors are interested in selecting individual stocks for their own portfolios, but aren't sure where to begi
12-Mar-2018 10:08 AM

Diurnal appoints Worldwide as global contract research organisation

Diurnal Group announced Monday the appointment of the global contract research organisation (CRO), Worldwide Clinical Trials (Worldwide), as its preferred provider of clinical trial services to support the US clinical development of Chronocort. Worldwid
12-Mar-2018 09:06 AM

Diurnal operating losses grow amid increase in investment, creation of commercial unit

Diurnal Group reported a loss before tax of £7.8m for the six months ended 31 December 2017, wider than the £5.7m reported in the prior year period as operating losses grew to £7.7m from £5.7m. The wider operating loss came amid
19-Feb-2018 08:43 AM

Diurnal signs marketing, distribution agreement with Emerge Health

Diurnal Group secured a marketing and distribution agreement with leading specialised Australian pharmaceutical company Emerge Health for the commercialisation of Diurnal's novel therapies, Alkindi and Chronocort in Australia and New Zealand. Austra
13-Feb-2018 08:57 AM

Diurnal plans first launch of Alkindi for 2Q18 after receiving European marketing authorization

Diurnal Group plc announced Monday that the European Commission (EC) has granted a paediatric use marketing authorisation (PUMA) for Alkindi following the positive opinion issued by the European Medicines Agency (EMA) in December 2017. Diurnal said first
09-Jan-2018 07:28 AM

Diurnal reports positive data from Alkindi study

Diurnal Group has announced positive data from the food matrix compatibility study for Alkindi (development programme name: Infacort; hydrocortisone granules in capsules for opening) in healthy adult volunteers. It said this study supports the planned U
18-Dec-2017 11:10 AM

Broker Forecast - Numis issues a broker note on Diurnal Group Plc

Numis today reaffirms its buy investment rating on Diurnal Group Plc (LON:DNL) and set its price target at 185p. Story provided by
15-Dec-2017 01:18 PM

Diurnal receives positive CHMP opinion

IP Group said it has noted that Diurnal Group confirmed the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to the European Commission recommending Alkindi as replacement therapy for paediatric adrenal insufficiency (AI
21-Nov-2017 01:19 PM

Diurnal shareholders pass all resolutions at AGM

Diurnal Group has confirmed that all resolutions were passed by shareholders at today's Annual General Meeting. At 1:19pm: (LON:DNL) Diurnal Group Plc share price was 0p at 142.5p Story provided by
13-Oct-2017 09:08 AM

Diurnal schedules AGM

Diurnal Group will hold its annual general meeting at the offices of FTI Consulting LLP, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD on 21 Nov at 11.30 a.m. At 9:08am: (LON:DNL) Diurnal Group Plc share price was 0p at 134.5p Story provided by
06-Sep-2017 08:09 AM

Diurnal operating losses widen

Diurnal's operating losses rose to £12.1m in the year to the end of June - up from £7.0m in 2016. The the speciality pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases said the increase reflected i
14-Aug-2017 01:23 PM

Diurnal sets date of FY results announcement

Diurnal Group has confirmed that the Company intends to announce its financial results for the year ended 30 June on Wednesday, 6 September. At 1:23pm: (LON:DNL) Diurnal Group Plc share price was 0p at 132.5p Story provided by
15-Jun-2017 09:46 AM

Diurnal doses first patient in Infacort trial

Diurnal Group has successfully dosed the first patient in a food matrix compatibility study for Infacort in healthy volunteers. It said this study supported the planned US registration package for Infacort for the treatment of paediatric adrenal insuffi
13-Jun-2017 11:51 AM

Diurnal to present at the Shares Spotlight Evening in London on 21 June 2017

Shares and AJ Bell Media are pleased to present Berkeley Energia, Diurnal and Eurasia Mining at their evening event in London on Wednesday 21 June 2017. The evening event provides an opportunity for board directors from UK listed companies to make a pres
12-May-2017 09:40 AM

Broker Forecast - Cantor Fitzgerald issues a broker note on Diurnal Group Plc

Cantor Fitzgerald today initiates coverage of Diurnal Group Plc (LON:DNL) with a buy investment rating and price target of 208p. Story provided by
20-Mar-2017 11:20 AM

Broker Forecast - Numis issues a broker note on Diurnal Group Plc

Numis today reaffirms its buy investment rating on Diurnal Group Plc (LON:DNL) and cut its price target to 169p (from 187p). Story provided by
16-Mar-2017 07:26 AM

Clinigen and Diurnal partner for MA programme

Clinigen Group's Idis managed access division and Diurnal Group have partnered to launch a managed access programme in Europe for Infacort to treat paediatric patients with adrenal insufficiency (AI) and Chronocort to treat patients with congenital a

a d v e r t i s e m e n t